Survival of patients after high-risk melanoma is not improved by adjuvant bevacizumab.
Jody A. CharnowEditor https://www.dermatologyadvisor.com
Jody A. Charnow has been the editor of Renal & Urology News, a publication of Haymarket Media, since 2003. Previously, he had served as editor of Internal Medicine World Report and a managing editor for Medical Tribune. He holds a BA in biology from the State University of New York at Albany.